Observational study on the tolerability of cluster subcutaneous immunotherapy in patients with rhinoconjunctivitis with or without asthma sensitized to pollen: the SIMO study

Background The objective of this study was to determine whether a cluster scheme of allergic immunotherapy (AIT), starting administration of the therapeutic extract with the highest available concentration vial (vial B) of Allergovit®, affords adequate safety and tolerance under conditions of routine clinical practice.